688526.SHG Wuhan Keqian Biology Co Ltd
- Market cap
- CNY 5.45B
- P/E
- 23.9x
- P/B
- 1.33x
- ROE
- 5.7%
- Dividend yield
- 3.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688526.SHG undervalued?
Graham number688526.SHG trades 18.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Wuhan Keqian Biology Co Ltd fundamental analysis
No fundamental analysis for Wuhan Keqian Biology Co Ltd yet.
Wuhan Keqian Biology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. It offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.
Full company profileWuhan Keqian Biology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Wuhan Keqian Biology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 390M | 633M | 735M | 508M | 843M | 1.10B | 1.00B | 1.06B | 942M | 950M | 748M |
| Gross Profit | 307M | 529M | 612M | 398M | 692M | 873M | 722M | 743M | 581M | 950M | 444M |
| Operating Income | 210M | 377M | 452M | 279M | 524M | 661M | 467M | 459M | 439M | 478M | 201M |
| EBITDA | 222M | 400M | 486M | 315M | 557M | 725M | 569M | 579M | 551M | 585M | 258M |
| Net Income | 186M | 320M | 389M | 243M | 448M | 571M | 410M | 396M | 382M | 416M | 231M |
| EPS | 0.52 | 0.89 | 1.08 | 0.67 | 1.16 | 1.23 | 0.88 | 0.85 | 0.82 | 0.90 | 0.50 |
| Balance Sheet | |||||||||||
| Total Assets | 592M | 932M | 1.23B | 1.37B | 3.11B | 3.73B | 4.39B | 4.67B | 4.50B | 4.79B | 4.51B |
| Total Liabilities | 179M | 259M | 354M | 252M | 402M | 571M | 892M | 834M | 553M | -4.17B | 482M |
| Shareholders' Equity | 413M | 673M | 876M | 1.12B | 2.71B | 3.15B | 3.50B | 3.84B | 3.94B | 4.17B | 4.03B |
| Cash & Short-term Investments | 268M | 59.0M | 611M | 671M | 2.18B | 768M | 1.13B | 1.33B | 1.26B | 1.72B | 170M |
| Total Debt | - | 2.55M | - | - | 60.1M | 78.1M | 279M | 294M | 5.55M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 221M | 338M | 352M | 155M | 400M | 531M | 424M | 538M | 393M | 469M | - |
| Capital Expenditure | 29.1M | 129M | 31.4M | 138M | 112M | 374M | 103M | 105M | 107M | 124M | 71.1M |
| Free Cash Flow | 192M | 208M | 320M | 17.2M | 289M | 157M | 321M | 434M | 286M | 345M | 161M |
| Ratios | |||||||||||
| ROE | 45.1% | 47.6% | 44.4% | 21.7% | 16.5% | 18.1% | 11.7% | 10.3% | 9.7% | 10.0% | 5.7% |
| ROA | 31.4% | 34.4% | 31.6% | 17.7% | 14.4% | 15.3% | 9.3% | 8.5% | 8.5% | 8.7% | 5.1% |
| Net Profit Margin | 47.7% | 50.6% | 52.9% | 47.8% | 53.1% | 51.7% | 40.9% | 37.2% | 40.6% | 43.7% | 31.0% |
| Debt to Equity | - | 0.00x | - | - | 0.02x | 0.02x | 0.08x | 0.08x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Wuhan Keqian Biology Co Ltd dividends
- Dividend yield
- 3.66%
- Forward dividend
- 0.64 CNY
- Payout ratio
- 48.0%
- Ex-dividend date
- May 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 199M | 0.43 | 48.0% |
| 2024 | CNY 205M | 0.44 | 53.5% |
| 2023 | CNY 97.1M | 0.21 | 24.5% |
| 2022 | CNY 88.4M | 0.19 | 21.6% |
| 2021 | CNY 135M | 0.29 | 23.6% |
| 2020 | CNY 369K | 0.00 | 0.1% |
| 2019 | CNY 85.8M | 0.24 | 35.3% |
| 2018 | 122M | 0.34 | 31.4% |
| 2017 | 47.2M | 0.13 | 14.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Wuhan Keqian Biology Co Ltd
- Insiders 74.78%
- Institutions 0.77%
- Public & others 24.45%
- Shares outstanding 466M
- Free float 118M
Wuhan Keqian Biology Co Ltd company profile
- Company name
- Wuhan Keqian Biology Co Ltd
- Ticker
- 688526.SHG
- ISIN
- CNE1000042Q8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 950
- Fiscal year end
- December
- Address
- No. 419, Gaoxin 2nd Road, Wuhan, China, 430073
- Phone
- 86 27 8132 2942
- Website
- kqbio.com
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. It offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.
Wuhan Keqian Biology Co Ltd management
8- Ms. Mulin ChenGM & Chairman · born 1988
- Mr. Ming ZhongCFO, Deputy GM & Vice Chairman · born 1983
- Mr. Gaoyuan XuExecutive Vice President of R&D & Director of Core Technical Personnel · born 1976
- Ms. Tiantian ZouBoard Secretary · born 1983
- Mr. Guanping ChenDeputy General Manager · born 1967
- Mr. Xibiao TangDeputy General Manager · born 1980
- Mr. Deng HongDeputy General Manager · born 1984
- Chan Cha ChenAccounting Supervisor